Нежелани реакции, описани като много чести, са получени при повече от 1 от 10 пациенти (≥ 1/ 10).
(Note that numbers for Blood and Lymphatic System Disorders are described in a separate table of laboratory examinations) Adverse reactions described as very common were experienced in more than 1 in 10 patients (≥ 1/ 10).